Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

With the recent surge in popularity of weight loss drugs like Ozempic, altogether called GLP-1s, there has been renewed scientific interest in understanding how our bodies regulate muscle growth.

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Notably, the dip in Novo Nordisk’s stock has been attributed to subpar clinical trial results for its new weight-loss drug CagriSema along with patent concerns. That said, over the last three ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market. Learn more on RHHBY stock here.

Data from the National Health and Nutrition Examination study show that between 2021-2023 ... And what about the new weight loss drugs? The Kaiser Family Foundation reported in its spring 2024 ...

Taxpayers would fund popular weight-loss ... drugs can help manage obesity-related health problems means its submission will be successful. Tori Brown, Eli Lilly’s general manager for Australia ...